« Previous
Next »
Titles
- A sense of déjà vu: the debate surrounding state biosimilar substitution laws1
- Administrative rulemaking1
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents1
- Bending the curve: options for achieving savings and improving value in U.S. health spending1
- Biologics in perspective: the case for generic biologic drugs1
- Business of healthcare1
- CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Competitive bidding in drug procurement: evidence from China1
- Does Medicare Part D protect the elderly from financial risk?1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act1
- Fact sheet. The 340B Drug Pricing Program1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia1
- How Medicaid and CHIP shield children from the rising costs of prescription drugs1